Cannabidiol as an Adjunct for the Treatment of Anorexia Nervosa (CAFTAN): An Open Label Pilot Trial with extension in Young People
About this study
We are recruiting young individuals aged 12-18 years with anorexia nervosa who are about to initiate or prepared to commence Maudsley Family Based Treatment for the first time. This study aims to investigate whether the addition of cannabidiol (CBD) to Maudsley Family Based Treatment can alleviate anxiety in young persons with anorexia nervosa to enhance treatment outcomes.
Research TeamProf. Iain McGregor, Prof Sarah Maguire, Sarah-Catherine Rodan, Dr. Karen Spielman, Prof. Janice Russell
InstitutionThe University of Sydney
Websitehttps://caftanstudy.com.au
Ethics Approval NumberX21-0440
Funding SourceLambert Initiative for Cannabinoid Therapeutics and InsideOut Institute for Eating Disorders
Project Start Date1 April 2023
Project End Date30 October 2024
ParticipantsYoung persons aged between 12-18 years with anorexia nervosa
What is InvolvedParticipants will take CBD daily for three months during phase 1 re-feeding stage of treatment. The study medication will be provided monthly, delivered free of charge. CBD is non-intoxicating. Participants will not experience any psychoactive effects commonly associated with cannabis use.
Participants will be required to attend Maudsley Family Based Treatment sessions in the community with their therapist.
Patients will require a referral from their treating medical practitioner, confirming they are medically stable and will medically monitor the patient for the duration of the study.
Participants will be required to attend Maudsley Family Based Treatment sessions in the community with their therapist.
Patients will require a referral from their treating medical practitioner, confirming they are medically stable and will medically monitor the patient for the duration of the study.
LocationNew South Wales Community, Australia
Contact Details
caftan.study@sydney.edu.au